Screening of Valvular Heart Disease Using Single-channel Electrocardiogram
Launched by I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY · Jul 25, 2025
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a simple, one-lead electrocardiogram (ECG) — a test that records the heart’s electrical activity — can help detect problems with the heart valves, such as narrowing (stenosis) or leaking (regurgitation). The goal is to find specific patterns in the ECG that match with valve problems, which could make it easier and quicker to screen for these heart conditions.
People aged 18 and older who are receiving treatment as outpatients or in the hospital may be eligible to join, as long as they agree to participate and have no conditions that affect the quality of the tests, such as certain movement disorders or having a pacemaker. Participants will first have an ultrasound of the heart (echocardiogram) to carefully check valve function, followed immediately by a short, one-minute ECG recording using a small, single-lead device. The information collected will be analyzed without using personal details to protect privacy. This study involves over 1,200 people and aims to improve early detection of valve heart disease using a simple and accessible test.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The presence of written informed consent of the patient to participate in the study
- • Age from 18 years
- • Outpatient treatment and / or hospitalization in a research center
- Exclusion Criteria:
- • Reluctance of the patient to participate in the study
- • Poor quality ECG recording on a single-channel ECG monitor
- • Poor visualization of the heart during echocardiographic study
- • Acute psychotic reactions that arose during research
- • An exacerbation of chronic diseases requiring treatment tactics for the patient and preventing his further participation in the study.
- Non-inclusion criteria:
- • Poor quality ECG recording on a single-channel ECG monitor
- • Conditions that can impair ECG recording quality (Parkinson's disease, essential tremor)
- • Mental illness
- • Patients with a pacemaker installed
- • Patients with prosthetic valves
About I.M. Sechenov First Moscow State Medical University
i.m. Sechenov First Moscow State Medical University is a prestigious institution dedicated to advancing medical education, research, and clinical practice. As a leading center for medical innovation in Russia, the university fosters a collaborative environment for scientific inquiry and the development of novel therapies. With a commitment to high-quality clinical trials, i.m. Sechenov aims to contribute significantly to the global biomedical landscape by evaluating new treatments and improving patient care through rigorous research methodologies and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Trial Officials
Philipp Kopylov, Prof.
Study Director
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Natalia Kuznetsova, Dr.
Principal Investigator
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported